Effect of a thromboxane synthetase inhibitor, ozagrel hydrochloride, on peak expiratory flow in stable asthmatics treated with beclomethasone diproprionate
Steroid inhalation therapy is recommended for treatment of moderate to severe asthma, but it is unknown whether the therapy sufficiently suppresses production of thromboxane A2 (TXA2), one of the inflammatory lipid mediators. The effect of a selective orally active thromboxane synthesis inhibitor, o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
1997-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015315768 |